Abstract
Currently available options for the treatment of hyperparathyroidism secondary to chronic renal failure do not allow the achievement of target values for plasma calcium, phosphorus, and parathyroid hormone in the majority of patients with chronic kidney disease (CKD) stage 5. This is particularly true for CKD patients who have been referred to nephrologists late in the course of their disease and in whom prevention has not been possible. The advent of a new class of therapeutic agents, the calcimimetics, will allow an easier control of already established parathyroid overfunction, as has been demonstrated in several phase II studies and one phase III study with cinacalcet. Future studies will show whether an earlier start of treatment in patients with CKD stage 2, 3, and 4 allows the prevention of secondary hyperparathyroidism. Since all available experience has been gathered in adult patients it is also necessary to test the efficacy and safety of the calcimimetics in children with CKD.
Similar content being viewed by others
References
Moe SM, Drueke TB (2003) Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 23:369–379
Eknoyan G, Levin A, Levin NW (2003) Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1–201
Lorenzo V, Martin M, Rufino M, Jimenez A, Malo AM, Sanchez E, Hernandez D, Rodriguez M, Torres A (2001) Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 37:1260–1266
Cunningham J, Makin H (1997) How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant 12:16–18
Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 55:2169–2177
Atik A, Ghazali A, Achard JM, Rida Z, Oprisiu R, Brazier M, Leflon P, Gueris J, Moriniere P, Sari Z, Fournier A (1997) La déplétion relative en vitamine D native: un facteur de risque potentiel chez l’hémodialysé algérien de lésions radiologiques d’hyperparathyroïdie et d’ostéomalacie indépendant de la calcitriolémie. Nephrologie 18:47–52
Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456
Drueke TB, McCarron DA (2003) Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med 349:496–499
Argilés A, Kerr PG, Canaud B, Flavier JL, Mion C (1993) Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 43:630–640
Cunningham J, Beer J, Coldwell RD, Noonan K, Sawyer N, Makin HLJ (1992) Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 7:63–68
Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E (1997) Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66–71
Slatopolsky EA, Burke SK, Dillon MA (1999) RenaGel (R), a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55:299–307
Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252
Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N (2003) Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64:441–450
Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653–1661
D’Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int [Suppl] S73–S78
Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C (1989) Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36:1112–1118
Graham KA, Hoenich NA, Tarbit M, Ward MK, Goodship THJ (1997) Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 8:627–631
Brown EM, Pollak M, Riccardi D, Hebert SC (1994) Cloning and characterization of an extracellular Ca2+-sensing receptor from parathyroid and kidney: new insights into the physiology and pathophysiology of calcium metabolism. Nephrol Dial Transplant 9:1703–1706
Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88:5644–5649
Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575–583
Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium×phosphorus in secondary hyperparathyroidism. Kidney Int 63:248–254
Block GA, Martin KJ, deFrancisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) The calcimimetic cincalcet (AMG 073) for the treatment of secondary hyperparathyroidism in hemodialysis patients. N Engl J Med 350:1516–1525
Antonsen JE, Sherrard DJ, Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223–227
Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436–445
Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017–1024
Moe SM, Sprague SM, Cunningham J, Drueke TB, Adler S, Rosansky SJ, Albizem MB, Guo MD, Zani V, Goodman WG (2003) Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCl. J Am Soc Nephrol 14:463A
Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239–297
Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N (1998) NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448–453
Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977–2983
Martin D, Miller G, Colloton M, Shatzen E, Lacey D (2003) Cincacalcet HCl decreases parathyroid hyperplasia in a rodent model of chronic renal insufficiency (CRI). J Am Soc Nephrol 14:462A
Ogata H, Ritz E, Odoni G, Amann K, Orth SR (2003) Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14:959–967
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was presented in part at the IPNA Seventh Symposium on Growth and Development in Children with Chronic Kidney Disease: The Molecular Basis of Skeletal Growth, 1–3 April 2004, Heidelberg, Germany
Rights and permissions
About this article
Cite this article
Drüeke, T.B. Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means. Pediatr Nephrol 20, 399–403 (2005). https://doi.org/10.1007/s00467-004-1745-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-004-1745-0